# Sitagliptin for Hyperglycemia in Patients With T2DM Undergoing Cardiac Surgery

> **NCT02556918** · PHASE4 · COMPLETED · sponsor: **Emory University** · enrollment: 202 (actual)

## Conditions studied

- Hyperglycemia

## Interventions

- **DRUG:** Sitagliptin
- **DRUG:** Placebo
- **DRUG:** Regular Human Insulin
- **DRUG:** Insulin glargine
- **DRUG:** Supplemental insulin (Insulin lispro)
- **DRUG:** Supplemental insulin (Insulin aspart)

## Key facts

- **NCT ID:** NCT02556918
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01
- **Primary completion:** 2018-11-06
- **Final completion:** 2018-11-06
- **Target enrollment:** 202 (ACTUAL)
- **Last updated:** 2019-12-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02556918

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02556918, "Sitagliptin for Hyperglycemia in Patients With T2DM Undergoing Cardiac Surgery". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02556918. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*